Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
In medicine, a legacy effect is defined as the sustained beneficial effect of a given treatment on disease outcomes, even after cessation of the intervention. Initially described in optimized control of diabetes, it was also observed in clinical trials exploring intensification strategies for other...
Guardado en:
Autores principales: | Lucie Pothen, Jean-Luc Balligand |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0956d50ae29a4feca4d723245d92988d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Beneficial Effects of Angiotensin II AT1 Blocker on Cardiovascular Adverse Remodeling Due to Nitric Oxide Synthesis Blockade
por: Fernandes-Santos,Caroline, et al.
Publicado: (2006) -
Editorial: New Trends in the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease
por: Ewa Szczepanska-Sadowska, et al.
Publicado: (2021) -
Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy
por: Wang S, et al.
Publicado: (2021) -
The Emerging Scenario of the Gut–Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases
por: Thiago M. C. Pereira, et al.
Publicado: (2021) -
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells
por: Oghenemega Okoloko, et al.
Publicado: (2021)